View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
June 8, 2018updated 13 Jul 2022 9:14am

Janssen Biotech starts Phase lb trial of ADU-214 and nivolumab

Janssen Biotech has commenced a Phase lb trial designed to investigate the safety and efficacy of ADU-214 (JNJ-64041757) in combination with nivolumab to treat advanced lung cancer.

Janssen Biotech has commenced a Phase lb trial designed to investigate the safety and efficacy of ADU-214 (JNJ-64041757) in combination with nivolumab to treat advanced lung cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The trial is the result of an agreement signed between Janssen and the developer of ADU-214 Aduro Biotech in 2014. The deal has granted an exclusive, worldwide licence to Janssen for the further development of ADU-214.

The Phase lb, open-label, multi-centre trial aims to enrol 170 patients with mesothelin-positive, relapsed / refractory Stage IIIB or Stage IV adenocarcinoma of the lung.

Its primary endpoint is the percentage of participants with an objective response, which will be based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST); CR defined as disappearance of all target lesions.

“The Phase lb, open-label, multi-centre trial aims to enrol 170 patients with mesothelin-positive, relapsed / refractory Stage IIIB or Stage IV adenocarcinoma of the lung.”

The trial’s secondary endpoints include the percentage of participants with disease control (DC), duration of objective response (DOR), progression-free survival (PFS), overall survival (OS) and others.

Aduro Biotech chairman, president and CEO Stephen Isaacs said: “Based on single agent data from a Phase l dose-escalation study in patients with advanced-stage relapsed or refractory non-small cell lung presented at the 2017 International Association for the Study of Lung Cancer’s World Conference, Janssen made the decision to advance ADU-214 in combination with an anti-PD-1 checkpoint inhibitor.

“The initial data demonstrated that five out of nine patients treated with single agent ADU-214 achieved a best response of stable disease, with one patient having received 25 cycles of treatment at the time of data cut off.”

Aduro Biotech aims to complete the trial by 2022.

ADU-214 is an immunotherapy developed using Aduro’s live, attenuated, double-deleted Listeria (LADD) technology platform, while nivolumab is a PD-1 immune checkpoint inhibitor developed by Bristol-Myers Squibb .

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena